Plasma VEGF determination in disseminated lymphangiomatosis-Gorham-Stout syndrome: A marker of activity? A case report with a 5-year follow-up

Bone

Volumn 46, Issue 3, 2010, Pages 873-876

  Dupond, Jean Louis ^a   Bermont, Laurent ^a   Runge, Michel ^a   de Billy, Marjolaine ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Gorham Stout disease; Interferon alpha 2b; Lymphangiomatosis; Vascular endothelial growth factor

Indexed keywords

ALPHA2B INTERFERON; VASCULOTROPIN; BIOLOGICAL MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; ARTICLE; BONE DISEASE; CASE REPORT; DISEASE ACTIVITY; DRUG DOSE REDUCTION; FEMALE; FOLLOW UP; GORHAM STOUT SYNDROME; HUMAN; LYMPHANGIOMATOSIS; MEDIASTINUM DISEASE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RETROPERITONEAL DISEASE; SOFT TISSUE DISEASE; SPLEEN DISEASE; SYSTEMIC DISEASE; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; OSTEOLYSIS; SYNDROME;

BIOLOGICAL MARKERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LYMPHANGIOLEIOMYOMATOSIS; MIDDLE AGED; OSTEOLYSIS, ESSENTIAL; SYNDROME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77649186870     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2009.11.015     Document Type: Article

References (20)

1. Devaney K., Vinh T.H., Sweet D.E. Skeletal-extraskeletal angiomatosis. A clinicopathological study of fourteen patients and nosologic considerations. J. Bone Joint Surg. Am. 1994, 76:876-891.
2. Faul J.L., Berry G.J., Colby T.S., Ruoss S.J., Walter M.B., Rosen G.D., et al. Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis and lymphatic dysplasia syndrome. Am. J. Respir. Crit. Care Med. 2000, 161:1037-1046.
3. Gorham L.W., Wright A.W., Schultz H.H., Maxon F.C. Disappearing bone. A rare form of massive osteolysis. Am. J. Med. 1954, 17:674-682.
4. Cannon S.R. Massive osteolysis: a review of seven cases. J. Bone Joint Surg. Br. 1986, 68:25-28.
5. Aviv R.I., Mchungh K., Hunt J. Angiomatosis of bone and soft tissue: a spectrum of disease from diffuse lymphangiomatosis to vanishing bone disease in young patients. Clin. Radiol. 2001, 56:184-190.
6. Ezekowitz R.A., Mulliken J.B., Folkman J. Interferon alpha 2a-therapy for life-threatening hemangiomas of infancy. N. Engl. J. Med. 1992, 326:1456-1463.
7. Laverdiere C., David M., Dubois J., Russo P., Hershon L., Lapierre J.G. Improvement of disseminated lymphangiomatosis with recombinant interferon therapy. Pediatr. Pulmonol. 2000, 29:321-324.
8. Timke C., Krause M.T., Opperman H.C., Leuschner I., Claviez A. Interferon alpha 2b treatment in a eleven-year-old boy with disseminated lymphangiomatosis. Pediatr. Blood Cancer 2007, 48:108-111.
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 2004, 25:581-611.
10. Stacker S.A., Achen M.G., Jussilia L., Baldwin M.E., Alitalo K. Lymphangiogenesis and cancer metastasis. Nat. Rev., Cancer 2002, 2:573-583.
11. Colucci S., Taraboletti G., Primo L., Viale A., Rocca C., Valdembri D., et al. Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. J. Bone Miner. Res. 2006, 21:207-218.
12. Shin J.W., Huggenberger R., Detmar M. Transcriptional profiling of VEGF-A and VEGF-C target genes in lymphatic endothelium reveals endothelial specific molecule-1 as a novel mediator of lymphangiogenesis. Blood 2008, 112:2318-2326.
13. Ozeki M., Funato M., Kanda K., Ito M., Teramoto T., Kaneko H., et al. Clinical improvement of diffuse lymphangiomatosis with pegylated interferon alpha-2b therapy. Case report and review of the literature. Pediatr. Hematol. Oncol. 2007, 24:513-524.
14. Takahashi A., Ogawa C., Kanazawa T., Watanabe H., Suzuki M., Suzuki N., et al. Kuwano H remission induced by interferon alpha in a patient with massive osteolysis and extension of lymph-hemangiomatosis: a severe case of Gorham-Stout syndrome. J. Pediatr. Surg. 2005, 40:E47-E50.
15. Radhakrishnan K., Rockson G. Gorham's disease: an osseous disease of lymphangiogenesis. Ann. N.Y. Acad. Sci. 2008, 1131:203-205.
16. Barleon B., Sozzani S., Zhou D., Weich H.A., Mantovani A., Marmé D. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996, 87:3336-3343.
17. Von Marshall Z., Scholtz A., Cramer T., Schäfer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J. Natl. Cancer Inst. 2003, 95:437-448.
18. Cao B., Chen X.P., Zhu P., Ding L., Guan J., Shi Z.L. Inhibitory effect of interferon alpha-2b on expression of cyclo-oxygenase-2 and vascular endothelial growth factor in human hepatocellular carcinoma inoculated in nude mice. World J. Gastroenterol. 2008, 44:6802-6807.
19. Raig E.T., Jones N.B., Varker K.A., Benninger K., Go M.R., Biber J.L., et al. VEGF secretion is inhibited by interferon alpha in several melanoma cell lines. J. Interferon Cytokine Res. 2008, 28:553-561.
20. Shao X.J., Lu W.Q., Liu C. Different effects of angiogenesis inhibitors INF-alpha and TIMP-1 on lymphangiogenesis. Lymphology 2008, 41:64-74.